866-997-4948(US-Canada Toll Free)

Global Clostridium Diagnostics Market 2017-2021

Published By :

Technavio

Published Date : Jul 2017

Category :

In Vitro Diagnostics

No. of Pages : 91 Pages

About Clostridium Diagnostics
Clostridium is a gram-positive bacteria that belongs to the Firmicutes phylum. There are multiple species of Clostridium Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, and Clostridium sordellii, which are responsible for numerous infections. Clostridium tetani is responsible for tetanus, Clostridium botulinum causes botulism, Clostridium perfringes leads to gas gangrene, Clostridium sortellii causes pneumonia, endocarditis, arthritis, peritonitis, and myonecrosis, and Clostridium difficile is responsible for diarrhea.

Technavios analysts forecast the global clostridium diagnostics market to grow at a CAGR of 14.71% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global clostridium diagnostics market for 2017-2021. To calculate the market size, the report considers the sales/volume/value.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Clostridium Diagnostics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Abbott
Beckman Coulter
Olympus
Siemens Healthineers
F. Hoffmann-La Roche

Other prominent vendors
BD
bioMerieux
Chrono-log Corporation
Corgenix
Diazyme Laboratories
FUJIREBIO DIAGNOSTICS
Hologic
QIAGEN
Sysmex Corporation
Thermo Fisher Scientific
Market driver
Rising prevalence of Clostridium-related diseases
For a full, detailed list, view our report

Market challenge
High cost of molecular diagnostics over immunoassays
For a full, detailed list, view our report

Market trend
Technological advancements
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.




Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
Market outline
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Market segmentation by technology
Immunoassays
Molecular diagnostics
PART 07: Market segmentation by product
Clostridium difficile
Clostridium perfringens
Clostridium botulinum
Clostridium tetani
Clostridium sordellii
PART 08: Market segmentation by end-user
Hospitals
Independent laboratories
Physicians' clinics
PART 09: Geographical segmentation
Market overview
Americas
EMEA
APAC
PART 10: Decision framework
PART 11: Drivers and challenges
Market drivers
Market challenges
PART 12: Market trends
Technological advancements
Increasing focus on reducing nosocomial infections
Growing popularity of portable POCT products
PART 13: Vendor landscape
Competitive landscape
PART 14: Key vendor analysis
Abbott
Beckman Coulter
Olympus Corporation
Siemens Healthineers
F. Hoffmann-La Roche
Other prominent vendors
PART 15: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Global Clostridium diagnostics market: Overview
Exhibit 02: Human pathogenic Clostridium species
Exhibit 03: Global Clostridium diagnostics market 2016-2021 ($ millions)
Exhibit 04: Five forces analysis
Exhibit 05: Global Clostridium diagnostics market by technology 2016 (%)
Exhibit 06: Global immunoassays market: Overview
Exhibit 07: Global Clostridium diagnostics market by immunoassays 2016-2021 ($ millions)
Exhibit 08: Diagnostic tests for Clostridium difficile
Exhibit 09: Global molecular diagnostics market: Overview
Exhibit 10: Global Clostridium diagnostics market by molecular diagnostics 2016-2021 ($ millions)
Exhibit 11: FDA-approved nucleic acid-based tests for diagnosis of Clostridium difficile
Exhibit 12: Global Clostridium difficile diagnostics market 2016-2021 ($ millions)
Exhibit 13: Global Clostridium perfringens diagnostics market 2016-2021 ($ millions)
Exhibit 14: Global Clostridium botulinum diagnostics market 2016-2021 ($ millions)
Exhibit 15: Global Clostridium tetani diagnostics market 2016-2021 ($ millions)
Exhibit 16: Global Clostridium sordellii diagnostics market 2016-2021 ($ millions)
Exhibit 17: Global Clostridium diagnostics market by geography 2016 (%)
Exhibit 18: Global Clostridium diagnostics market by geography 2021 (%)
Exhibit 19: Global Clostridium diagnostics market by geography 2016-2021 ($ millions)
Exhibit 20: Global Clostridium diagnostics market by geography 2016-2021 (%)
Exhibit 21: Clostridium diagnostics market in Americas ($ millions)
Exhibit 22: Clostridium diagnostics market in US: Overview
Exhibit 23: Clostridium diagnostics market in EMEA ($ millions)
Exhibit 24: Clostridium diagnostics market in Germany: Overview
Exhibit 25: Clostridium diagnostics market in APAC ($ millions)
Exhibit 26: Clostridium diagnostics market in Japan: Overview
Exhibit 27: Abbott: Key highlights
Exhibit 28: Abbott: Strength assessment
Exhibit 29: Abbott: Strategy assessment
Exhibit 30: Abbott: Opportunity assessment
Exhibit 31: Beckman Coulter: Key highlights
Exhibit 32: Beckman Coulter: Strength assessment
Exhibit 33: Beckman Coulter: Strategy assessment
Exhibit 34: Beckman Coulter: Opportunity assessment
Exhibit 35: Olympus Corporation: Key highlights
Exhibit 36: Olympus Corporation: Strength assessment
Exhibit 37: Olympus Corporation: Strategy assessment
Exhibit 38: Olympus Corporation: Opportunity assessment
Exhibit 39: Siemens Healthineers: Key highlights
Exhibit 40: Siemens Healthineers: Strength assessment
Exhibit 41: Siemens Healthineers: Strategy assessment
Exhibit 42: Siemens Healthineers: Opportunity assessment
Exhibit 43: F. Hoffmann-La Roche: Key highlights
Exhibit 44: F. Hoffmann-La Roche: Strength assessment
Exhibit 45: F. Hoffmann-La Roche: Strategy assessment
Exhibit 46: F. Hoffmann-La Roche: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *